Eli Lilly lifts revenue forecast by $5bn on weight-loss demand

Eli Lilly raised its 2026 revenue forecast by $5bn to $91bn-$92bn as Mounjaro and Zepbound demand drove a quarterly beat. More than 500,000 patients joined its Medicare obesity-drug pilot.